The Impact of Type 2 Diabetes in Parkinson's Disease
Dilan Athauda(The Francis Crick Institute), Sonia Gandhi(The Francis Crick Institute), Thomas Foltynie(National Hospital for Neurology and Neurosurgery), Gurvir S. Virdi(The Francis Crick Institute), James R. Evans(The Francis Crick Institute), Khalida Ismail(Diabetes UK), Yoav Ben‐Shlomo(University of Bristol), Donald G. Grosset(University of Glasgow), Christine Girges(National Hospital for Neurology and Neurosurgery), Anna I. Wernick(The Francis Crick Institute), Huw R. Morris(University College London), Michael Lawton(University of Bristol), Minee L. Choi(Korea Advanced Institute of Science and Technology), Nirosen Vijiaratnam(Western Health)
Cited by 131
Related Papers
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort
|Brain|2009|962
Mechanism of Oxidative Stress in Neurodegeneration
|Oxidative Medicine and Cellular Longevity|2012|940
The epidemiology of Parkinson's disease
|The Lancet|2024|809